Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Dexcom (DXCM) Capital Expenditures (2016 - 2025)

Historic Capital Expenditures for Dexcom (DXCM) over the last 17 years, with Q4 2025 value amounting to $101.9 million.

  • Dexcom's Capital Expenditures fell 1821.83% to $101.9 million in Q4 2025 from the same period last year, while for Dec 2025 it was $363.5 million, marking a year-over-year increase of 130.99%. This contributed to the annual value of $363.5 million for FY2025, which is 130.99% up from last year.
  • As of Q4 2025, Dexcom's Capital Expenditures stood at $101.9 million, which was down 1821.83% from $80.5 million recorded in Q3 2025.
  • Dexcom's Capital Expenditures' 5-year high stood at $124.6 million during Q4 2024, with a 5-year trough of $50.4 million in Q3 2023.
  • Its 5-year average for Capital Expenditures is $85.6 million, with a median of $89.2 million in 2022.
  • In the last 5 years, Dexcom's Capital Expenditures soared by 20030.12% in 2021 and then tumbled by 5341.96% in 2023.
  • Dexcom's Capital Expenditures (Quarter) stood at $80.2 million in 2021, then fell by 20.82% to $63.5 million in 2022, then decreased by 17.32% to $52.5 million in 2023, then skyrocketed by 137.33% to $124.6 million in 2024, then decreased by 18.22% to $101.9 million in 2025.
  • Its last three reported values are $101.9 million in Q4 2025, $80.5 million for Q3 2025, and $94.1 million during Q2 2025.